The DOI matches its Crossref record; 146 of the 146 references it cites were found in a registry or an index.
Gene therapy clinical trials worldwide to 2017: An update
Abstract
To date, almost 2600 gene therapy clinical trials have been completed, are ongoing or have been approved worldwide. Our database brings together global information on gene therapy clinical activity from trial databases, official agency sources, published literature, conference presentations and posters kindly provided to us by individual investigators or trial sponsors. This review presents our analysis of clinical trials that, to the best of our knowledge, have been or are being performed worldwide. As of our November 2017 update, we have entries on 2597 trials undertaken in 38 countries. We have analysed the geographical distribution of trials, the disease indications (or other reasons) for trials, the proportions to which different vector types are used, and the genes that have been transferred. Details of the analyses presented, and our searchable database are available via The Journal of Gene Medicine Gene Therapy Clinical Trials Worldwide website at: http://www.wiley.co.uk/genmed/clinical. We also provide an overview of the progress being made in gene therapy clinical trials around the world, and discuss key trends since the previous review, namely the use of chimeric antigen receptor T cells for the treatment of cancer and advancements in genome editing technologies, which have the potential to transform the field moving forward.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“About 18.5% of clinical trials use this vector for gene therapy [57].”
From The Ocular Gene Delivery Landscape (2021) · cites this paper as [57]
In the citing paper
“Furthermore, some viral vectors (eg, Adenovirus vector, Herpesviral vector) are toxic and can be immunogenic.”
From Viral Vector Systems for Gene Therapy: A Comprehensive Literature Review of Progress and Biosafety Challenges (2020) · cites this paper as [22]
In the citing paper
“The AV vector now represents 1 of the 3 major viral vector categories in the gene therapy toolbox, along with AAV and lenti/retrovirus vector systems.”
From Viral Vector Systems for Gene Therapy: A Comprehensive Literature Review of Progress and Biosafety Challenges (2020) · cites this paper as [22]
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Research works printed but not linked: 6
- Aiuti A, 2009, Ten years of gene therapy for primary immune deficiencies. Hematology 2009 – the Education Program of the American Society of Hematology, Education Program, 2009, 682
- GeorgeLA RagniMV Samelson‐JonesBJ et al.Preliminary results from a phase 1/2 dose escalation trial of an investigational AAV‐mediated gene therapy for hemophilia A. American Society of Hematology 59th Annual Meeting and Exposition. Online Conference Proceedings; 9 December2017.https://ash.confex.com/ash/2017/webprogram/Paper108679.html[30 January 2018].
- Constable IJ, 2016, Phase 2a randomized clinical trial: safety and post hoc analysis of subretinal rAAV.sFLT‐1 for wet age‐related macular degeneration. E, Biol Med, 14, 168
- MonahanP WalshCE PowellJS et al.Update on a phase 1/2 open‐label trial of BAX335 an adeno‐associated virus 8 (AAV8) vector‐based gene therapy program for hemophilia B. Proceedings of the XXV International Society on Thrombosis and Haemostasis Conference.North Carolina USA:Carrboro;2015;13(Suppl 2): LB010):87.
- Abeona Therapeutics.Abeona Therapeutics Receives Regulatory Approval to Initiate Clinical Trial in Australia with ABO‐102 Gene Therapy For Patients with MPS IIIA: Clinical Trial Notification (CTN) Enables Initiation at 3rd Global Site and Accelerates Enrollment in the ABO‐102 MPS IIIA Gene Therapy Program. Abeona Therapeutics: Press Release 9 May2017.https://globenewswire.com/news-release/2017/05/09/980972/0/en/Abeona-Therapeutics-Receives-Regulatory-Approval-to-Initiate-Clinical-Trial-in-Australia-with-ABO-102-Gene-Therapy-For-Patients-with-MPS-IIIA.html[3 April 2018].
- Amgen.FDA Approves IMLYGIC™ (Talimogene Laherparepvec) As First Oncolytic Viral Therapy In The US. AMGEN website: Press Release 27 October2015.http://www.amgen.com/media/news‐releases/2015/10/fda‐approves‐imlygic‐talimogene‐laherparepvec‐as‐first‐oncolytic‐viral‐therapy‐in‐the‐us/[30 January 2018].
Cited by
Sorted by citations
Items 401–500 of 903
Vupputuri, S., Tayebi, L., Koralege, R. S. H., Nigatu, A. S., Mozafari, M., Mishra, A., Liu, L., & Ramsey, J. D. (2021) · Journal of Nanoparticle Research · doi:10.1007/s11051-020-05134-9 · Cited by 14
The role of gap junctions in cell death and neuromodulation in the retina
Szarka, G., Balogh, M., Tengölics, Á. J., Ganczer, A., Völgyi, B., & Kovács‐Öller, T. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.308069 · Cited by 16
Boonstra, E., Hatano, H., Miyahara, Y., Uchida, S., Goda, T., & Cabral, H. (2021) · Journal of Materials Chemistry B · doi:10.1039/d1tb00645b · Cited by 14
Progress of oncolytic virotherapy for neuroblastoma
Chen, X., Dai, S.-Y., Zhan, Y., Yang, R., Chen, D.-Q., Li, Y., Zhou, E. Y., & Dong, R. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.1055729 · Cited by 14
Gene therapy and nasopharyngeal carcinoma
Hughes, J., Alusi, G., & Wang, Y. (2012) · Rhinology Journal · doi:10.4193/rhino11.239 · Cited by 14
Is Malaysia Ready for Human Gene Editing: A Regulatory, Biosafety and Biosecurity Perspective
Kalidasan, V., & Das, K. T. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.649203 · Cited by 18
Pol, T., Chonkaew, W., Hocharoen, L., Niamnont, N., Butkhot, N., Roshorm, Y. M., Kiatkamjornwong, S., Hoven, V. P., & Pratumyot, K. (2022) · ACS Omega · doi:10.1021/acsomega.1c06101 · Cited by 13
Chitosan-Based Nanocomposites for Biological Applications
Yalçın, S., & Çankaya, N. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.106379 · Cited by 13
Monfared, Y. K., Mahmoudian, M., Cecone, C., Caldera, F., Haiaty, S., Heidari, H. R., Rahbarghazi, R., Matencio, A., Zakeri‐Milani, P., & Trotta, F. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122690 · Cited by 13
Eş, İ., Thakur, A., Khaneghah, A. M., Foged, C., & de la Torre, L. G. (2024) · Biotechnology Advances · doi:10.1016/j.biotechadv.2024.108342 · Cited by 13
Rasizadeh, R., Aghbash, P. S., Mokhtarzadeh, A., Poortahmasebi, V., Oskouee, M. A., Nahand, J. S., Amini, M., Mahdavi, S. Z. B., Yari, A. H., & Baghi, H. B. (2024) · Gene · doi:10.1016/j.gene.2024.148904 · Cited by 13
Precise Enzymatic Cleavage Sites for Improved Bioactivity of siRNA Lipo-Polyplexes
Reinhard, S., Wang, Y., Dengler, S., & Wagner, E. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00585 · Cited by 13
Limb-girdle Muscular Dystrophy and Therapy: Insights into Cell and Gene-based Approaches
Taheri, F., Taghizadeh, E., Pour, M. J. R., Rostami, D., Renani, P. G., Rastgar‐Moghadam, A., & Hayat, S. M. G. (2020) · Current Gene Therapy · doi:10.2174/1566523220666200218113526 · Cited by 13
Chanut, F. J.-A., Sanvito, F., Ferrari, G., Visigalli, I., Carriglio, N., Hernández, R. J., Norata, R., Doglioni, C., Naldini, L., & Cristofori, P. G. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.135 · Cited by 13
Capone, F., Nappi, F., & Galli, M. C. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-812034-7.00011-x · Cited by 15
Li, Q., Grant, M. B., Richards, E. M., & Raizada, M. K. (2020) · Clinical Science · doi:10.1042/cs20200570 · Cited by 13
Massa, M., Rivara, M., Donofrío, G., Cristofolini, L., Peracchia, E., Compari, C., Bacciottini, F., Orsi, D., Franceschi, V., & Fisicaro, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063062 · Cited by 13
Leite, R. A. (2008) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2008.tde-27112008-165017 · Cited by 13
Agboola, O. E., Agboola, S. S., Odeghe, O. B., Olaiya, O. E., Ayinla, Z. A., Akinsanya, P. O., Ilesanmi, O. S., Kehinde, I. O., Adegbuyi, A. T., Kolawole, O. A., et al. (2025) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2025.08.001 · Cited by 14
Gene Therapy: A New Approach in Modern Medicine
Yazdani, A., Alirezaie, Z., Motamedi, M. J., & Amani, J. (2018) · International Journal of Medical Reviews · doi:10.29252/ijmr-050304 · Cited by 15
Yamazaki, T., Biswas, M., Kosugi, K., Nagashima, M., Inui, M., Tomono, S., Takagi, H., Ichimonji, I., Nagaoka, F., Ainai, A., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.606518 · Cited by 12
Zhang, W., Lin, L., Zhang, Y., Zhao, T., Zhan, Y., Wang, H., Fang, J., & Du, B. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112973 · Cited by 12
Toma, I., Porfire, A. S., Tefas, L. R., Berindan‐Neagoe, I., & Tomuță, I. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071482 · Cited by 12
Gene therapy approaches for equine osteoarthritis
Thampi, P., Samulski, R. J., Grieger, J. C., Phillips, J. N., McIlwraith, C. W., & Goodrich, L. R. (2022) · Frontiers in Veterinary Science · doi:10.3389/fvets.2022.962898 · Cited by 14
Toward gene therapy for congenital thrombotic thrombocytopenic purpura
Dekimpe, C., Roose, E., Sakai, K., Tersteeg, C., Meyer, S. F. D., & Vanhoorelbeke, K. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2022.12.018 · Cited by 12
Unexplored power of CRISPR-Cas9 in neuroscience, a multi-OMICs review
Banazadeh, M., Abiri, A., Poortaheri, M. M., Asnaashari, L., Langarizadeh, M. A., & Forootanfar, H. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.130413 · Cited by 12
The future of complement therapeutics
Kolev, M. V., Rao, K. N., Yeh, M. W., Parikh, A., & Deschatelets, P. (2024) · Exploration of Immunology · doi:10.37349/ei.2024.00161 · Cited by 13
siRNA-based nanotherapeutic approaches for targeted delivery in rheumatoid arthritis
Sawan, S., Kumari, A., Majie, A., Ghosh, A., Karmakar, V., Kumari, N., Ghosh, S., & Gorain, B. (2024) · Biomaterials Advances · doi:10.1016/j.bioadv.2024.214120 · Cited by 15
Genetic advancements in breast cancer treatment: a review
Shokoohi, M., Sedaghatshoar, S., Arian, H., Mokarami, M., Habibi, F., & Bamarinejad, F. (2025) · Discover Oncology · doi:10.1007/s12672-025-01884-x · Cited by 14
Zhao, Y., Liu, H., Zhao, C., Dang, P., Li, H., & Farzaneh, M. (2019) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x15666191224122058 · Cited by 12
Non-invasive gene delivery across the blood-brain barrier: present and future perspectives
Kimura, S., & Harashima, H. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.320981 · Cited by 12
Polymer-based non-viral vectors for gene therapy in the skin
Tortajada, L., Felip‐León, C., & Vicent, M. J. (2022) · Polymer Chemistry · doi:10.1039/d1py01485d · Cited by 12
Eş, İ., Malfatti-Gasperini, A. A., & de la Torre, L. G. (2022) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2022.112476 · Cited by 14
Synthetic biodegradable polymeric materials in non-viral gene delivery
Panchal, S. S., & Vasava, D. V. (2023) · International Journal of Polymeric Materials · doi:10.1080/00914037.2023.2167081 · Cited by 14
Enhancing pDNA Delivery with Hydroquinine Polymers by Modulating Structure and Composition
Roy, P., Kreofsky, N. W., Brown, M. E., Bruggen, C. V., & Reineke, T. M. (2023) · JACS Au · doi:10.1021/jacsau.3c00126 · Cited by 12
Designing cytochrome P450 enzymes for use in cancer gene therapy
Carrera-Pacheco, S. E., Mueller, A., Puente-Pineda, J. A., Zúñiga-Miranda, J., & Guamán, L. P. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1405466 · Cited by 12
Purification of therapeutic adenoviruses using laterally-fed membrane chromatography
Kawka, K., Madadkar, P., Umatheva, U., Shoaebargh, S., Medina, M. F. C., Lichty, B. D., Ghosh, R., & Latulippe, D. R. (2019) · Journal of Membrane Science · doi:10.1016/j.memsci.2019.02.056 · Cited by 12
Ramos‐Valle, A., Marín‐Caba, L., García‐Hevia, L., Correa‐Duarte, M. A., & Fanárraga, M. L. (2023) · Materials Today Advances · doi:10.1016/j.mtadv.2023.100357 · Cited by 11
Cell-cell interaction in the pathogenesis of inherited retinal diseases
Du, X., Butler, A. G., & Chen, H. Y. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1332944 · Cited by 12
Yuen, B. P., Wong, K., So, Y.-M., Kwok, W.-H., Cheung, H. W., Wan, T. S. M., Ho, E. N. M., & Wong, W. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c00247 · Cited by 11
Adenoviral Vectors for Gene Therapy of Hereditary Diseases
Muravyeva, A., & Smirnikhina, S. (2024) · Biology · doi:10.3390/biology13121052 · Cited by 11
Lee, M., Kim, Y.-S., Lee, K., Kang, M., Shin, H., Oh, J.-W., Koo, H., Kim, D., Kim, Y., Kong, D., et al. (2019) · Cancers · doi:10.3390/cancers11081090 · Cited by 11
Prospects of Non-Coding Elements in Genomic DNA Based Gene Therapy
Simna, S. P., & Han, Z. (2021) · Current Gene Therapy · doi:10.2174/1566523221666210419090357 · Cited by 11
Understanding Post Entry Sorting of Adenovirus Capsids; A Chance to Change Vaccine Vector Properties
Daussy, C. F., Pied, N., & Wodrich, H. (2021) · Viruses · doi:10.3390/v13071221 · Cited by 12
Steffes, V. M., Zhang, Z., Ewert, K. K., & Safinya, C. R. (2023) · Langmuir · doi:10.1021/acs.langmuir.3c02664 · Cited by 10
Mojarrad, M., Qomi, S. B., & Asghari, A. (2019) · Advanced Biomedical Research · doi:10.4103/abr.abr_41_19 · Cited by 12
Chen, Y., Yang, Z., Dong, Y., & Chen, Y. (2020) · BMC Biotechnology · doi:10.1186/s12896-020-00620-3 · Cited by 11
Akwiditya, M. A., Yong, C. Y., Yusof, M. T., Mariatulqabtiah, A. R., Ho, K. L., & Tan, W. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052320 · Cited by 11
A Review of Brain-Targeted Nonviral Gene-Based Therapies for the Treatment of Alzheimer’s Disease
Arora, S., Sharma, D., Layek, B., & Singh, J. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00611 · Cited by 11
Feng, Y. (2019) · Current Gene Therapy · doi:10.2174/1566523219999190426144513 · Cited by 11
Editorial: Non-viral vectors for gene therapy/nucleic acid delivery
Poddar, A., Banerjee, R., & Shukla, R. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1304769 · Cited by 11
Ultrasound-enhanced gene transfection: vectors, methods, and biomedical applications
Wu, J., Gao, Y., Zhou, H., Yang, Z., Rodriguez, R. D. D., Xu, X., Ma, L., & Qiu, L. (2025) · Ultrasonics Sonochemistry · doi:10.1016/j.ultsonch.2025.107607 · Cited by 11
Kadkhodazadeh, M., Mohajel, N., Behdani, M., Baesi, K., Khodaei, B., Azadmanesh, K., & Arashkia, A. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1039324 · Cited by 10
Perturbation of mRNA splicing in liver cancer: insights, opportunities and challenges
Jia, Q., Sun, X., Li, H., Guo, J., Niu, K., Chan, K. M., Bernards, R., Qin, W., & Jin, H. (2024) · Gut · doi:10.1136/gutjnl-2024-333127 · Cited by 10
Click-Shielded and Targeted Lipopolyplexes
Klein, P. M., & Wagner, E. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9670-4_8 · Cited by 10
The advent of automated medicine? The values and meanings of precision
Prainsack, B. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780198863465.003.0015 · Cited by 11
Advanced Gene Therapy Strategies for the Repair of ACL Injuries
Amini, M., Venkatesan, J. K., Liu, W., Leroux, A., Nguyễn, T. N., Madry, H., Migonney, V., & Cucchiarini, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214467 · Cited by 12
Vaz, T. A. G., Rodrigues, A. F., & Coroadinha, A. S. (2023) · Biotechnology Journal · doi:10.1002/biot.202300212 · Cited by 10
Frequency and Pattern of Worldwide Ocular Gene Therapy Clinical Trials up to 2022
Ameri, H., Kesavamoorthy, N., & Bruce, D. N. (2023) · Biomedicines · doi:10.3390/biomedicines11123124 · Cited by 10
Novel AAV variants with improved tropism for human Schwann cells
Drouyer, M., Chu, T., Labit, E., Haase, F., Navarro, R. G., Nazareth, D., Rosin, N. L., Merjane, J., Scott, S., Cabanes‐Creus, M., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101234 · Cited by 10
Self-citationGenetic doping: WADA we do about the future of ‘cheating’ in sport?
Brown, J. (2019) · The International Sports Law Journal · doi:10.1007/s40318-019-00141-y · Cited by 10
Peripapillary Intravitreal Injection Improves AAV-Mediated Retinal Transduction
Madrakhimov, S. B., Yang, J. Y., Ahn, D. H., Han, J. W., Ha, T. H., & Park, T. K. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.018 · Cited by 10
Uğurlu, Ö., Barlas, F. B., Evran, S., & Tımur, S. (2020) · Plasmid · doi:10.1016/j.plasmid.2020.102513 · Cited by 10
Hosseinpour, S., Xu, C., & Walsh, L. J. (2021) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2020.112108 · Cited by 10
Selecting a Cell Engineering Methodology During Cell Therapy Product Development
Timmins, L. M., Burr, A., Carroll, K., Keefe, R., Teryek, M., Cantolupo, L. J., van der Loo, J. C. M., Heathman, T. R. J., Gormley, A. J., Smith, D. W., et al. (2021) · Cell Transplantation · doi:10.1177/09636897211003022 · Cited by 10
Self-assembled PEGylated amphiphilic polypeptides for gene transfection
Klemm, P., Behnke, M., Solomun, J. I., Bonduelle, C. V., Lecommandoux, S., Traeger, A., & Schubert, S. (2021) · Journal of Materials Chemistry B · doi:10.1039/d1tb01495a · Cited by 10
Zhang, Y., Yuan, Z., Jin, Y., Zhang, W., & Yuan, W. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122058 · Cited by 10
An SI-traceable reference material for virus-like particles
Briones, A., Martos, G., Bedu, M., Choteau, T., Josephs, R. D., Wielgosz, R. I., & Ryadnov, M. G. (2022) · iScience · doi:10.1016/j.isci.2022.104294 · Cited by 10
Multifunctional Delivery Systems for Cancer Gene Therapy
McErlean, E. M., McCrudden, C. M., & McCarthy, H. O. (2015) · InTech eBooks · doi:10.5772/61297 · Cited by 10
Lv, B., Li, J., Li, M., Zhuo, Y., Ren, K., Li, E., & Yang, G. (2018) · Scientific Reports · doi:10.1038/s41598-018-28421-x · Cited by 10
Akbulut, H., Cihan, A. Ç., Şahin, G., Tang, Y., & İçlı, F. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.245 · Cited by 10
Gerpe, M. C. R., van Lieshout, L. P., Domm, J. M., van Vloten, J. P., Datu, J., Ingrao, J. C., Yu, D. L., de Jong, J., Moraes, T. J., Krell, P. J., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.211 · Cited by 10
Impact of gene therapy for canine monogenic diseases on the progress of preclinical studies
Switonski, M. (2020) · Journal of Applied Genetics · doi:10.1007/s13353-020-00554-8 · Cited by 12
García-Pérez, L., Ordas, A., Canté-Barrett, K., Meij, P., Pike‐Overzet, K., Lankester, A. C., & Staal, F. J. T. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12060549 · Cited by 11
CRISPR—a challenge for national and international regulation
Nicol, D. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780198863465.003.0014 · Cited by 9
Tools shaping drug discovery and development
Cheung, E., Xia, Y., Caporini, M. A., & Gilmore, J. L. (2022) · Biophysics Reviews · doi:10.1063/5.0087583 · Cited by 9
Precise Gene Knock‐In Tools with Minimized Risk of DSBs: A Trend for Gene Manipulation
Liu, Y. H., Kong, J., Liu, G., Li, Z., & Xiao, Y. (2024) · Advanced Science · doi:10.1002/advs.202401797 · Cited by 10
Retroviral Vector Technology for Gene Therapy: History, Current Landscape, and Future Prospects
Jaballah, S. A., Ali, L. M., Jehad, M. A., Akhlaq, S., Rizvi, T. A., & Mustafa, F. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169473 · Cited by 10
Vetores virais para uso em terapia gênica
Oliveira, B. D. A., França, E. D. S., Souza, V. G., Vallinoto, A. C. R., & da Silva, A. N. M. R. (2018) · Revista Pan-Amazônica de Saúde · doi:10.5123/s2176-62232018000200008 · Cited by 9
Cell and gene therapy manufacturing capabilities in Australia and New Zealand
O’Sullivan, G. M., Velickovic, Z., Keir, M., Macpherson, J. L., & Rasko, J. E. J. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2019.10.010 · Cited by 9
Combining gene therapy with other therapeutic strategies and imaging agents for cancer theranostics
Azevedo, A., Farinha, D., Geraldes, C. F. G. C., & Faneca, H. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120905 · Cited by 9
Vogt, H. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780198863465.003.0005 · Cited by 11
van Heuvel, Y., Schatz, S., Hein, M. D., Dogra, T., Kazenmaier, D., Tschorn, N., Genzel, Y., & Stitz, J. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1076524 · Cited by 12
Bioinspired Approaches for Central Nervous System Targeted Gene Delivery
Kumar, J., Karim, A., Sweety, U. H., Sarma, H., Nurunnabi, M., & Narayan, M. (2023) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c00842 · Cited by 9
An integrative method to predict signalling perturbations for cellular transitions
Zaffaroni, G., Okawa, S., Morales‐Ruiz, M., & del Sol, A. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz232 · Cited by 9
Brokowski, C., & Adli, M. (2020) · The CRISPR Journal · doi:10.1089/crispr.2019.0051 · Cited by 10
Lai, W., Fang, C., Chou, M.-C., Lin, M.-C., Shen, C., Chao, C., Jou, Y., Chang, D., & Wang, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-91328-7 · Cited by 9
Ladd, B. K., Bowes, K., Lundgren, M., Gräslund, T., & Chotteau, V. (2022) · Processes · doi:10.3390/pr10030515 · Cited by 9
Mekkaoui, L., Tejerizo, J. G., Abreu, S., Rubat, L., Nikoniuk, A., Macmorland, W., Horlock, C., Matsumoto, S., Williams, S., Smith, K., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.12.006 · Cited by 9
Farraha, M., Barry, M. A., Lu, J., Pouliopoulos, J., Le, T. Y. L., Igoor, S., Rao, R., Kok, C., Chong, J. J. H., & Kizana, E. (2019) · Gene Therapy · doi:10.1038/s41434-019-0097-0 · Cited by 8
Yong, K. S., & Sung, W. K. (2019) · doi:10.46619/cmj.2019.2-1007 · Cited by 9
Preclinical models for studying corticosteroid‐induced osteonecrosis of the femoral head
Tsubosaka, M., Maruyama, M., Lui, E., Kushioka, J., Toya, M., Gao, Q., Shen, H., Li, X., Chow, S. K., Zhang, N., et al. (2023) · Journal of Biomedical Materials Research Part B Applied Biomaterials · doi:10.1002/jbm.b.35360 · Cited by 8
Nanotechnology-enabled miRNA delivery systems next-generation molecular strategies in cancer therapy
Kuran, S. A., Adıyıl, R., Zıkşahna, K., Özkan, M., & Ihlamur, M. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152923 · Cited by 10
Pengnam, S., Plainwong, S., Patrojanasophon, P., Rojanarata, T., Ngawhirunpat, T., Radchatawedchakoon, W., Niyomtham, N., Yingyongnarongkul, B., & Opanasopit, P. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118798 · Cited by 8
Regenerative Medicine and Angiogenesis; Focused on Cardiovascular Disease
Moradi, S. Z., Jalili, F., Hoseinkhani, Z., & Mansouri, K. (2021) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2022.072 · Cited by 9
Current advances in microbial-based cancer therapies
Shahbaz, A., Mahmood, T., Javed, M. U., & Abbasi, B. H. (2023) · Medical Oncology · doi:10.1007/s12032-023-02074-x · Cited by 8
Gene therapy approaches for GM1 gangliosidosis: Focus on animal and cellular studies
Hosseini, K., Fallahi, J., Tabei, K., & Razban, V. (2023) · Cell Biochemistry and Function · doi:10.1002/cbf.3887 · Cited by 8
Therapeutic potential of oncolytic viruses in the era of precision oncology.
Kingsak, M., Meethong, T., Jongkhumkrong, J., Li, C., & Wang, Q. (2023) · PubMed Central · doi:10.12336/biomatertransl.2023.02.003 · Cited by 8
A cellular disease model toward gene therapy of TGM1-dependent lamellar ichthyosis
Sercia, L., Romano, O., Marini, G., Enzo, E., Forcato, M., Rosa, L. D., & Luca, M. D. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101311 · Cited by 9
Metadata
- Authors
- Ginn, S. L., Amaya, A. K., Alexander, I. E., Edelstein, M., & Abedi, M. R.
- Affiliations
- The University of Sydney (AU)
- Chatham House (GB)
- Uppsala University Hospital (SE)
- Corresponding author
- Ginn, Samantha L.
- Venue
- The Journal of Gene Medicine
- Publisher
- Wiley
- Published
- 2018-04-19
- Volume
- 20
- Issue
- 5
- Pages
- e3015-e3015
- ISSN
- 1099-498X (ISSN-L)
- 1521-2254
- OpenAlex
- W2983048398
- Cited by
- 903
- References
- 146
- Citations by year
- 2026: 31 · 2025: 68 · 2024: 86 · 2023: 77 · 2022: 124 · 2021: 141 · 2020: 151 · 2019: 148 · 2018: 36
- FWCI
- 16.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Gene Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- gene therapy, clinical trials, clinical trial database, gene therapy vectors, disease indications, chimeric antigen receptor T cells, cancer immunotherapy, genome editing, clinical trial trends
- MeSH terms
- Clinical Trials as Topic, Humans, Neoplasms, Global Health, Genetic Therapy, Immunotherapy, Adoptive, Outcome Assessment, Health Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review